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Background: To evaluate tolerability and maintenance of dose intensity of 2 weekly treatment with vincristine,
doxorubicin, cyclophosphamide alternating with ifosfamide, etoposide (VDC/IE) in patients with advanced small
round cell sarcomas including Ewing family tumours (EFT), desmoplastic small round cell tumours (DSRCT) and
undifferentiated high grade round cell sarcomas (UHGRCS).
Methods: Retrospective review of 16 patients treated at a single centre with VDC/IE. Dose received, treatment
delay, toxicity and clinical outcome were recorded for each cycle up to a maximum of 14 cycles.
Results: A total 193 cycles of VDC/IE were administered to 10 patients with EFT, 4 with DSRCT and 2 with UHGRCS.
Median age was 22 years with 75% over 18 years. Metastases were present in 14 patients. The mean duration of
each cycle was 16.7 days. Febrile neutropenia occurred in 14 % of cycles, and grade 3/4 haematologic toxicity
including anaemia and thrombocytopenia in 16 % and 11 % of cycles respectively. Seven patients had a dose
reduction. Five patients discontinued VDC/IE early due to toxicity.
Conclusions: This schedule of VDC/IE is feasible in patients with EFT and DSRCT including adults and those with
metastases. Its comparison with other standard regimens for these diseases is justified.
Keywords: Ewing’s sarcoma, Desmoplastic small round cell tumour, Chemotherapy, SarcomaBackground
The Ewing’s family of tumours (EFT) are the second
most common malignant bone tumour seen in children
and young people [1,2]. Histologically, they are charac-
terized by small round blue cells with immunohisto-
chemical staining for CD99 and neural markers. A
reciprocal translocation between chromosomes 11 and
22 is evident in more than 85% of these tumours [3,4].
The family of small round blue cell sarcomas also includes
desmoplastic small round cell tumour (DSRCT), a rare
soft tissue sarcoma characteristically presenting in young
males with extensive multifocal intraabdominal disease.* Correspondence: jeremy.whelan@uclh.nhs.uk
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reproduction in any medium, provided the orSimilar chemotherapy approaches to those utilized for
EFT are used, albeit with less satisfactory results as pro-
gression and ultimately death due to disease is almost
universal [5-7].
Since the introduction of multimodality treatment in
EFT, survival has improved from 10% to 75 % in patients
with localized disease [8-11]. Since the 1980’s, chemo-
therapy regimens have evolved both in Europe and the
United States to include anthracyclines and alkylating
agents with only modest variations in dose and schedule
[9,10,12-15]. To contend with a lack of recent survival
improvement or new agents with major activity, investi-
gators have concentrated on investigating the benefits of
scheduling and dose intensity.
The current European Ewing tumour Working Initia-
tive of National Groups 1999 (EURO-EWING 99) studyl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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intensive induction regimen (VIDE, vincristine, ifosfa-
mide, doxorubicin and etoposide) and, in selected
cohorts of randomized patients, high dose chemotherapy
with stem cell rescue. Toxicity associated with VIDE
chemotherapy is substantial. For example, neutropenia
and related fever is reported in 60.8% and 65.8% of
courses respectively [16].
In North America, alternative approaches to dose
optimization have been explored. The Children’s Oncol-
ogy Group (COG) study, INT-0154, using a regimen of
vincristine, doxorubicin, cyclophosphamide alternating
with ifosfamide and etoposide (VDC/IE), randomized
patients to an increased treatment intensity by higher
doses of cyclophosphamide and ifosfamide and a
decreased length of treatment to 11 cycles over 30 weeks
in the test arm compared with a standard 17 cycles over
48 weeks but with equivalent total drug doses in each
arm. There was no survival improvement but more tox-
icity in the dose intense arm [17]. In contrast a survival
advantage has been reported in the preliminary results
from a further COG study of patients with localized
EFT, AEWSOO31, randomizing between a standard
three weekly schedule and an ‘interval compressed’ two
weekly schedule of VDC/IE, the latter made possible by
growth factor support [18]. The mean cycle durations
were 18.5 and 23.3 days for the two and three weekly
cycles respectively. Event free survival at 3 years was sig-
nificantly extended in the two weekly arm, 76% vs. 65%,
p = 0.028. Toxicity was similar in the two treatment
arms but with the reported frequency of febrile neutro-
penia and other major toxicities apparently lower than
those seen with VIDE. Interval compressed VDC/IE has
consequently been adopted as the standard of care for
future studies of EFT by COG.
There are significant advantages to defining a standard
chemotherapy regimen for EFT, not least as a platform
for testing new agents in an international setting, which
is essential in studying rare cancers. Additional goals for
all investigators are reducing both short and late toxicity
in a young population of whom approximately two
thirds will achieve long term survival, and of course lim-
iting the treatment burden in those with poor prognostic
factors. Whether interval compressed VDC/IE is less
toxic than VIDE is speculative in the absence of com-
parative data. Furthermore, the AEWS0031 study was
limited to patients with localised disease and had only a
small proportion of patients aged over 20 years, so it
may not be appropriate to extrapolate the data to the en-
tire EFT population.
In preparation for a planned randomized comparison
in Europe of first line treatment for EFT between VIDE
and VDC/IE, we retrospectively examined the feasibility
of interval compressed VDC/IE in patients withmetastatic EFT. In recognition that less toxic treatment
would be appropriate for older patients [19] and those
with a poor prognosis, we did not restrict the age of our
cohort, and also included those with DSRCT. This latter
group responds temporarily to chemotherapy regimens
used in EFT but with a 5-year survival of only 15% [20].
Our institutional standard for DSRCT and UHGRCS
includes treatment with VIDE. Identifying a more toler-
able but effective regimen is a priority.Materials and methods
Patient selection
A consecutive series of patients were treated with inter-
val compressed VDC/IE if either ineligible for the
EURO-EWING 99 study (including those with extrapul-
monary metastases), or were newly diagnosed with
DSRCT or UHGRCS. A histological diagnosis was
required in all patients. Staging included plain X-rays
and magnetic resonance imaging (MRI) or computed
tomography (CT) scan of the primary site, chest CT scan
and whole body technetium (99m Tc) bone scan were
performed to confirm the presence of metastases. Rou-
tine assessments of renal and cardiac function were con-
ducted at baseline, during and after therapy. Institutional
ethics guidance was followed.Chemotherapy
The VDC/IE regimen was alternate 14 day cycles of
VDC (vincristine 1.4mg/m2, maximum 2mg, doxorubi-
cin 75mg/m2 and cyclophosphamide 1200mg/m2 admi-
nistered over 2 days) and IE (ifosfamide 9gm/m2,
etoposide 500mg/m2 fractionated over 5 days). Patients
had a full blood count measured on the day prior to the
cycle due date and treatment was given if the neutrophil
count was greater than 1 × 109/l, platelet count greater
than 80 × 109/l and biochemical parameters were within
normal range. Nadir blood counts were not routinely
measured. All patients received growth factor support
with pegylated granulocyte colony stimulating factor
given within 72 h of last chemotherapy. Toxicity was
assessed using the Common Terminology Criteria for
Adverse Events (CTCAE) Version 3.0. In the event of
lack of recovery from toxicity, chemotherapy was
delayed or modified at the discretion of the treating
physician. Radiological response assessment was carried
out with restaging CT and MRI scans after 4 and 8
cycles of treatment. Fourteen cycles of chemotherapy
were planned subject to tolerability and response, with
treatment interrupted after 6 cycles or 12 weeks for sur-
gery if applicable. When radiotherapy was the primary
modality for local control, this was given concurrently
with chemotherapy beginning after cycle 6 and with the
omission of anthracyclines from relevant cycles.
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Patient characteristics
Between September 2008 and October 2011, 16 patients
received 193 cycles of interval-compressed VDC/IE
(Table 1). Ten patients had EFT, two had UHGRCS, and
four patients had DSRCT. Fourteen (88%) had meta-
static disease and 11 patients had more than one site of
metastasis. The remaining three had metastatic disease
confined to the lung. Seventy per cent of patients were
older than 18 years (median 22 years).
Treatment
Eight patients completed 14 cycles of VDC/IE (Table 2).
Six patients discontinued VDC/IE early, 5 due to toxicity
and one because of progression. These six received a
median of 11 cycles (range 4–12). Patient 3 had earlyTable 1 Patient demographics
No. of patients (n = 16) %
Age in years























Bone only 5 36%
Lung and bone 3 21%
Lung, bone, BM 2 14%
Bone and BM 1 7%
Lung only 3 21%
UHGRCS,Undifferentiated high grade round cell sarcoma; DSRCT, Desmoplastic
small round cell tumour; BM, bone marrow.surgery after 4 cycles having experienced severe haem-
atological and gastrointestinal toxicity. Chemotherapy
was not continued post operatively and the patient
remains disease free at 2 years. Patient 11 discontinued
after cycle 11 due to prolonged thrombocytopenia fol-
lowing pelvic irradiation. Patient 2 completed 12 cycles
and then developed a deep infection around a pelvic spa-
cer inserted for radiotherapy. Patients 14 and 15 also
completed 11 and 12 cycles respectively experiencing se-
vere cumulative fatigue and haematological toxicity. Pa-
tient 5 had progressive disease after 11 cycles. Two
patients with EFT were switched to receive VDC/IE hav-
ing previously commenced alternative chemotherapy
regimens and did not complete all 14 cycles. Patient 6
had 3 cycles of VIDE followed by 8 cycles of VDC/IE and
patient 16 had a cycle of VAC (vincristine, actinomycin-
D, cyclophosphamide), then VID (vincristine, ifosfamide,
doxorubicin) followed by 12 cycles of VDC/IE.
Treatment interval
The mean treatment interval for each patient was calcu-
lated from the entire treatment duration in days divided
by the number of cycles that were completed in this
time. The mean interval between cycles was 16.7 days
(range 14 to 57 days). All 16 patients took longer than
expected to complete the treatment course. Figure 1
demonstrates the total number of days delay over the
entire treatment schedule for each patient. The number
of days that treatment was delayed due to chemotherapy
related toxicity and other causes are demonstrated for
each patient in Figure 2. The main chemotherapy related
cause for delay was neutropenia, febrile neutropenia and
thrombocytopenia. Of the non-chemotherapy related
causes, most delays were due to surgery. Chemotherapy
was continued during and after radiotherapy in all but
one patient who developed prolonged thrombocytopenia
following pelvic radiotherapy.
Dose modifications
Nine patients (56%), including 5 of the 8 who completed
all 14 cycles, had no dose reduction, whereas 7 patients
required varying dose reductions, as follows. Patient 1
required a 50% dose reduction of vincristine alone at
cycle 3 due to grade 3 neuropathy but later recovered
and received full dose vincristine for all future cycles.
However she required a 20% dose reduction of ifosfa-
mide and etoposide at cycle 8 due to grade 3
thrombocytopenia, anaemia and mucositis. The dose re-
duction continued for cycle 10 and a further 20% reduc-
tion was made at cycle 12 for on-going grade 3 bone
marrow toxicity but the patient completed 14 cycles. Pa-
tient 2 had a 20% dose reduction of doxorubicin and
cyclophosphamide at cycles 7, 9 and 11. At cycle 10 a
20% reduction of Ifosfamide and etoposide was added























1 14 F EFT Kidney Bone,
peritoneum
No 14 19.9 Yes Surgery, R1 resection, poor respo se
to chemo on histology
Relapsed 3 months after completing VDC/IE –
receiving palliative chemotherapy
2 22 M EFT Ilium Lung, bone,
BM
No 12 17.1 Yes RT - 50Gy in 30# 2 phases Relapsed 10 months post treatment and died
23 months post treatment
4 29 M EFT Femur Bone, BM No 14 14.9 Yes Surgery, R0 resection with good
response to chemo on histology
Relapsed 7 months post treatment and died
11 months after treatment
5 15 F EFT Unknown Lung, Bone,
BM
No 11 17.5 Yes None Progressed at cycle 11 and died 3 months
later
6 17 M EFT Ilium Bone Yes 8 15.4 No RT 55Gy in 31# Relapsed 4 month post treatment. Died 15
months after completing treatment.
7 29 M EFT ilium Lung, Bone No 14 16.5 Yes RT 45Gy in 25# Progressed at the end of treatment and died
3 months later
11 21 M EFT Sacrum bone No 11 17.4 No RT 50.4Gy in 28# in 2 phases to
sacrum and 55Gy in 30# to chest
Relapsed 4 months post treatment and died 6
months post treatment
12 19 M EFT Pelvis Bone No 14 16.5 No RT 55Gy in 30# Disease free at 4 months post treatment
15 19 M EFT Metatarsal Lung, Bone No 12 17.9 No Surgery, close margins, poor
response to chemo on histology
Relapsed in lung 11 months treatment and
then lost to follow up in 8 months after
relapse as living abroad.
16 17 M EFT First rib Bone Yes 12 18.5 Yes RT 55.8Gy in 31# Died of disease 4 months after completing
treatment.
3 37 F UHGRCS Ilium none No 4 16.2 No Surgery, R0 resection. Poor
response to chemo on histology
Disease free 25 months post treatment
14 27 F UHGRCS mediastinum None No 11 19.9 Yes Surgery, R0 resection with
excellent response to chemo
on histology
Disease free 1 month post treatment
8 24 M DSRCT n/a Peritoneal
cavity,
lungs
No 14 15.9 No None Progressed 5 months post treatment, while
on maintenance VAC chemotherapy and is
having further palliative chemo
9 31 M DSCRT n/a Peritoneal
cavity Lung,
bone
No 14 15 No None Progressed 4 months post treatment and is
currently having further palliative chemo
10 19 M DSCRT n/a Peritoneal
cavity, liver
No 14 14.9 No None No progression 6 months post treatment on
maintenance VAC
13 22 M DSCRT n/a Peritoneal
cavity
No 14 14.9 No None No evidence of progression one month post
treatment




















Figure 1 Duration of treatment. The expected duration of
treatment for each patient in days, determined by the number of
cycles received (dark grey), and the additional days required to
complete treatment (light grey).
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episodes of febrile neutropenia and fatigue. Treatment
was terminated at cycle 12 due to a prolonged infection
surrounding his pelvic spacer. Patient 4 had a 20% dose
reduction of doxorubicin alone at cycles 9 and 11 due to
febrile neutropenia. Doxorubicin was omitted for cycle
13 as the patient was receiving concurrent radiotherapy.
Patient 5 had the first cycle of VDC with a 20% reduc-
tion of all three drugs due to poor performance status.
Subsequent cycles were given at full dose till cycle 7
when vincristine was dose reduced by 50% due to grade
3 peripheral neuropathy. This reduction continued for
cycle 9 and 11 when treatment was discontinued due to
progressive disease. Patient 7 had a 20% dose reduction
of doxorubicin at cycle 13 alone due to a grade 3
thrombocytopenia and neutropenia. He completed 14
cycles in total. Patient 14 experienced grade 3 peripheral
neuropathy at cycle 3 which led to a 50% dose reduction
of vincristine and subsequent omission from a further 4
cycles of VDC. By the end of treatment, the neuropathyFigure 2 Reasons for Delay. Delay in days is divided between
chemotherapy related toxicity (light grey) and other factors such as
interruptions for surgery (dark grey).had improved to grade 2. No other dose modifications
were made and she requested discontinuation of treat-
ment at cycle 11 due to cumulative fatigue and haemato-
logical toxicity. Finally, patient 16 had a 20% dose
reduction from cycle 5 in all drugs except vincristine be-
cause of grade 3 thrombocytopenia and mucositis.
Adverse events
There were no toxicity related deaths. The rates of grade
3 and 4 toxicities per cycle are illustrated in table 3.
Grade 3 febrile neutropenia was observed in 26 cycles
(13.5%) and there were 6 episodes of non-neutropenia
related infection requiring admission to hospital. Grade
3/4 anaemia was recorded in 31 cycles (16%) and
thrombocytopenia in 25 cycles (13%) on routine pre-
chemotherapy blood counts performed on day 14. Grade
3 or 4 mucositis was observed in only 12 cycles (6.2%).
There were no grade 3 and 4 cardiac or renal toxicities
and no episodes of grade 3 and 4 encephalopathy.
Outcome
All 10 patients with EFT had a radiological response to
therapy (Table 2). Nine patients subsequently had local
treatment to the primary site. Three patients had sur-
gery, with a good response to chemotherapy (>90% ne-
crosis) evident in one. The remaining six patients had
radiotherapy to the primary site. The tenth patient with
EFT had widely metastatic disease with no identifiable
primary tumour. Nine patients have relapsed or pro-
gressed between 1 and 11 months after completing treat-
ment and seven have died.
The four patients with DSCRT all completed 14 cycles
of treatment. All had clinical benefit from chemotherapy.
Two patients with high grade undifferentiated round
cell tumours were treated. The first had stable diseaseTable 3 Number of cycles complicated by grade 3 or 4
toxicity out of the total of 193 delivered cycles of VDC/IE
Grade 3 & 4 Toxicity
rates/193 cycles
Grade 3 Grade 4 Total
Grade 3
and 4 (%)
Febrile Neutropenia 26 0 26 (13.5)
Non-febrile neutropenia 3 11 14 (7.3)
Anaemia 29 2 31 (16.1)
Thrombocytopenia 19 6 25 (13.0)
Mucositis 12 0 12 (6.2)
Non-neutropenic infection
requiring hospital admission
6 0 6 (3.1)
Neuropathy 3 0 3 (1.6)
Fatigue 3 0 3 (1.6)
Diarrhoea 2 0 2 (1.0)
Nausea and vomiting 2 0 2 (1.0)
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poor histological response. This patient remains progres-
sion free after 25 months. The second patient underwent
surgery after 8 cycles, with a complete histological re-
sponse and is free from progression 3 months after com-
pletion of chemotherapy.
Discussion
In response to emerging data from the US indicating
that interval compressed VDC/IE was a well-tolerated,
effective regimen for EFT, we selected patients who were
ineligible for randomisation in Euro EWING 99 to re-
ceive this treatment in preference to the institutional
standard, VIDE [16,21]. We wished to gain preliminary
experience of the feasibility of this regimen and extend
its use to a population with metastatic disease and older
patients, groups not represented in the randomised
study from COG. The results indicate that this regimen
can be safely delivered and interval compression
achieved in this patient group. Although this is a small
study, these data also lend support to the view that this
is a tolerable regimen, even in an older patient group
with considerable disease burden. Finally, we observed
clinical benefit of dose compressed VDC/IE in DSRCT.
Toxicities associated with VIDE are well recorded both
from the initial single institution study [21] and from a
large analysis of the first 851 patients included in
EURO-E.W.I.N.G. 99 [16]. A total of 4,746 courses of
VIDE in 851 patients were analysed with respect to tox-
icity. The rate of febrile neutropenia was 60.8% with,
and 65.8% without, GCSF support.
Toxicity data from the AEWSOO31 study is currently
available only in abstract but reports a rate of grade 3/4
febrile neutropenia of 6.9% in the two weekly arm [18].
While emphasising the very small number of patients
reported here, this figure is lower than that reported
here (13.5%). However, the several differences in patient
demographics may account for this. Firstly the
AEWS0031 study was in a paediatric population with
only 75 of the 587 (12.8%) patients over the age of 18,
whereas in this study 12 patients were over the age of 18
(75%). Secondly, the AEWS0031 study was carried out
in patients who did not have metastatic disease. Again,
in our cohort, the majority of patients had metastatic
disease and a large overall tumour burden, 11 (69%)
patients having bone, bone marrow and lung metastases,
and 7 (44%) with primary pelvic disease.
The determinants of chemotherapy tolerance in EFT
require further clarification. Comparisons of the influ-
ence of factors such as age are limited by the absence of
planned prospective analyses and the reporting of
cohorts containing varying proportions of children, ado-
lescents and adults. Hence studies that report the ad-
verse influence of younger age may contain few adults[22]; others focus exclusively on much older adults [23];
while still others fall between these extremes [19,24]. In
the largest study, from EURO-E.W.I.N.G. 99, chemo-
therapy toxicity was not clearly greater in older patients
but dose modifications were more frequent [16]. Most
clinicians will remain cautious when treating older
patients or those with heavy tumour burden with the
current intensive regimens discussed here.
The treatment interval for the two weekly regimen was
successfully maintained in this patient cohort with a mean
treatment interval of 16.7 days. This resulted in a shorter
overall treatment time when compared to a 3-weekly
regimen. For the 8 patients who completed all 14 cycles
of treatment the average overall treatment time was 253
days, which is markedly shorter than the 294 days it
takes to complete standard treatment with VIDE/VAI.
In the EURO-E.W.I.N.G 99 clinical trial, dose modifica-
tions were recorded in 1020 of the 4746 courses (21%)
of all cycles. In this study, only 26 cycles were given at a
reduced dose (14%), therefore we can postulate that
dose intensity was not compromised in order to main-
tain a shorter dose interval. Three patients terminated
treatment early due to chemotherapy-related toxicity;
two at cycle 11 and one at cycle 12.
The main limitation of this study is that it is a small
non-randomised cohort of patients with heterogeneity of
presenting clinical features. The poor prognostic factors
present in several patients and the need to gain familiar-
ity with the regimen will have had an effect on the appli-
cation of clinical thresholds for decisions on dose
reductions and cessation of treatment. The information
on clinical outcome is provoking but should be consid-
ered only with caution. Despite this, the data do have
value in supporting the premise that this may be a less
toxic regimen than VIDE, which is deliverable in
patients outside of the limited eligibility criteria for
AEWS0031.
In conclusion, this study demonstrates that interval
compression of chemotherapy is feasible in an older and
higher risk cohort of patients with EFT and other small
round cell sarcomas. This schedule appears well toler-
ated compared with the standard European treatment of
VIDE followed by VAC or VAI. We also included
patients who would traditionally have a poor long term
survival even with intensive chemotherapy. A shorter,
less toxic regimen is an attractive option for these
patients in whom life expectancy is likely to be limited
by their disease. Further data regarding efficacy and long
term toxicity will be available in the future as this regi-
men will now be compared with the VIDE/VAI schedule
in a multi-centre randomised controlled trial.Competing interest
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